Immunization and Vaccine-Preventable Diseases Practice Questions

Q: An immunization session where 40 children are scheduled to be vaccinated in 2 hours by 2 ANMs is planned. Due to overcrowding, there is long waiting time, missed opportunities, and increased vaccine wastage. Which of the following is the most appropriate measure to reduce missed opportunities and vaccine wastage?

Assign one ANM for documentation and one for vaccination. ### ***Assign one ANM for documentation and one for vaccination*** - Dividing roles allows one staff member to focus on the systematic **screening, counseling, and record-keeping** (documentation/HMIS entry), while the other focuses exclusively on **safe and efficient vaccine administration**. - This streamlining reduces bottlenecks, minimizes **waiting time** for caregivers, ensures compliance with **cold chain protocols** through better oversight, and ultimately decreases **vaccine wastage** by optimizing the flow of beneficiaries. *Increase the number of cold-chain carriers and extend the session time* - Extending session time is often logistically difficult in routine outreach settings and does not address the fundamental issue of workflow inefficiency. - Simply adding equipment (cold chain carriers) does not fix the bottleneck caused by the documentation process, which is the primary cause of delays and missed opportunities. *Limit the number of children to 20 per session* - Placing an arbitrary limit on the number of children ignores the goal of high coverage (universal immunization) and may lead to increased **missed opportunities** for those not reached. - Efficient management of the existing workload is preferred over reducing quotas, as long as staff capacity allows for the current load when properly organized. *Increase the dose per vial* - This is not a feasible or safe medical intervention; vaccine dosages are strictly determined by formulation, safety, and efficacy studies. - Altering dosages is prohibited and would not address the operational issues of overcrowding or administrative bottlenecks.

Q: What diphtheria antibody titer is considered optimally protective?

>0.1 IU/ml. **Explanation:** The protective efficacy of the diphtheria vaccine is directly correlated with the serum antitoxin concentration. In Community Medicine and Pediatrics, these titers are categorized into levels of protection: 1. **Correct Answer (A): >0.1 IU/ml** is considered the **optimal or full protective level**. At this concentration, an individual is highly unlikely to develop clinical diphtheria even upon exposure to toxigenic *Corynebacterium diphtheriae*. This is the standard target for long-term immunity following a complete primary series and boosters. 2. **Incorrect Options:** * **B (>0.01 IU/ml):** This is the **minimum protective level** (basic protection). While it may prevent death, it does not reliably prevent clinical disease in all individuals. * **C (>0.05 IU/ml):** This is an intermediate level often cited as "partial protection" but is not the standard threshold for "optimal" immunity. * **D (0.5 IU/ml):** This value is significantly higher than the required threshold for protection and is not used as a standard clinical benchmark for diphtheria immunity. **High-Yield Clinical Pearls for NEET-PG:** * **Schick Test:** Historically used to determine susceptibility to diphtheria. A positive test (inflammation) indicates a titer **<0.01 IU/ml** (susceptible), while a negative test indicates immunity. * **Vaccine Type:** Diphtheria toxoid is an **adsorbed vaccine** (using aluminum salts) to enhance immunogenicity. * **Storage:** It is highly heat-stable but **freeze-sensitive**. It must be stored at +2°C to +8°C; if frozen, the "Shake Test" is used to check for damage. * **Herd Immunity:** To prevent epidemics, a community coverage of approximately 70-75% is required.

Q: A neonate developed a side effect following BCG vaccination. Which of the following side effects is the neonate most likely to develop after vaccination?

Ulceration. **Explanation:** The BCG (Bacillus Calmette-Guérin) vaccine is a live attenuated vaccine derived from *Mycobacterium bovis*. Following intradermal administration, a predictable sequence of local reactions occurs, which are considered normal responses rather than adverse events. **Why Ulceration is the Correct Answer:** After vaccination, a papule forms at 2–3 weeks, which increases in size and eventually undergoes **ulceration** by 4–8 weeks. This ulcer is the most common "side effect" or expected reaction. It typically heals spontaneously within 6–12 weeks, leaving behind the characteristic permanent circular scar. **Analysis of Incorrect Options:** * **A. Fever:** Systemic reactions like fever are extremely rare following BCG vaccination. It is primarily a localized reaction. * **C. Osteomyelitis:** This is a very rare, late complication (1 in 1,000,000 doses) occurring due to hematogenous spread, usually seen in immunocompromised infants. * **D. Regional lymphadenitis:** While common (suppurative or non-suppurative), it occurs less frequently than the standard ulceration. It is considered a complication if the lymph nodes exceed 1.5 cm or become fluctuant. **High-Yield Clinical Pearls for NEET-PG:** * **Strain used in India:** Danis 1331 strain. * **Dose:** 0.05 ml for neonates (below 1 month) and 0.1 ml for infants above 1 month. * **Site/Route:** Left upper arm (deltoid region), strictly **intradermal** (using a tuberculin/Omega syringe). * **Protective Effect:** Highly effective against TB meningitis and miliary TB in children, but has variable efficacy against adult pulmonary TB. * **Contraindication:** BCG is contraindicated in symptomatic HIV-infected infants or those with known immunodeficiency.

Q: Which of the following is NOT true about measles?

Secondary attack rate is 30-40%. **Explanation:** The correct answer is **B (Secondary attack rate is 30-40%)** because this statement is factually incorrect. Measles is one of the most highly infectious diseases known to mankind. Its **Secondary Attack Rate (SAR)** in susceptible household contacts is **>80% (often cited as 90%)**, not 30-40%. **Analysis of Options:** * **Option A:** The incubation period of Measles is typically **10–14 days** (from exposure to onset of rash), making this a true statement. * **Option C & D:** The Measles vaccine is a **Live Attenuated vaccine** (Edmonston-Zagreb strain is commonly used in India). It is administered via the **Subcutaneous (SC)** route, usually at 9 completed months and 16-24 months. Both statements are true. **High-Yield Clinical Pearls for NEET-PG:** * **Infectivity Period:** From 4 days before to 4 days after the appearance of the rash. * **Koplik’s Spots:** Pathognomonic feature; small white spots on an erythematous base found on the buccal mucosa opposite the lower 2nd molars during the pre-eruptive stage. * **Vitamin A:** Supplementation is mandatory in measles management to prevent complications like blindness and reduce mortality. * **Complications:** The most common complication is **Otitis Media**; the most common cause of death is **Pneumonia**; the most serious delayed complication is **SSPE** (Subacute Sclerosing Panencephalitis). * **Isolation:** Respiratory isolation is required. Unlike chickenpox, the measles rash is not infectious; it is a result of the immune response.

Q: Which of the following statements is TRUE about acellular pertussis vaccine EXCEPT?

It is superior to whole-cell pertussis vaccine (wP).. **Explanation:** The question asks for the **FALSE** statement regarding the acellular pertussis vaccine (aP). **1. Why Option B is the Correct Answer (The False Statement):** While the acellular pertussis vaccine (aP) has a significantly **better safety profile** (fewer febrile seizures and local reactions), it is **immunologically inferior** to the whole-cell vaccine (wP). The wP vaccine induces a robust Th1/Th17 immune response and provides longer-lasting protection. In contrast, aP-induced immunity wanes faster, leading to a resurgence of pertussis in many developed countries. Therefore, saying aP is "superior" is incorrect in the context of efficacy and duration of protection. **2. Analysis of Other Options:** * **Option A (True):** The aP vaccine is primarily composed of **purified inactivated pertussis toxin (toxoid)**, along with other antigens like filamentous hemagglutinin (FHA) and pertactin. * **Option C (True):** In terms of immediate seroconversion, the acellular components are designed to confer a similar level of initial protective immunity as the cellular vaccine, though the durability differs. * **Option D (True):** aP is used for both the primary series (as DTaP) and as a booster dose (as Tdap) in adolescents and adults. **Clinical Pearls for NEET-PG:** * **wP vs. aP:** wP is used in India’s Universal Immunization Programme (UIP) due to its higher efficacy and lower cost. * **Adverse Effects:** wP is associated with "Persistent Crying" and "Hypotonic Hyporesponsive Episodes" (HHE); aP is preferred in private practice to minimize these. * **Contraindication:** Any pertussis vaccine is contraindicated if the child develops **encephalopathy** within 7 days of a previous dose.

Question 1

An immunization session where 40 children are scheduled to be vaccinated in 2 hours by 2 ANMs is planned. Due to overcrowding, there is long waiting time, missed opportunities, and increased vaccine wastage. Which of the following is the most appropriate measure to reduce missed opportunities and vaccine wastage?

Accepted Answer

Assign one ANM for documentation and one for vaccination

Answer

Increase the number of cold -chain carriers and extend the session time

Answer

Limit the number of children to 20 per session

Answer

Increase the dose per vial

Question 2

A 35-year-old healthcare worker from India is posted to a sub-Saharan African country for WHO work. She has never had yellow fever. What is the most appropriate vaccination strategy?

Accepted Answer

Single dose of yellow fever vaccine at least 10 days before travel

Answer

Two doses of yellow fever vaccine 4 weeks apart

Answer

Yellow fever immunoglobulin followed by vaccine

Answer

Yellow fever vaccine with booster after 10 years

Question 3

What diphtheria antibody titer is considered optimally protective?

Accepted Answer

>0.1 IU/ml

Answer

>0.01 IU/ml

Answer

>0.05 IU/ml

Answer

0.5 IU/ml

Question 4

A neonate developed a side effect following BCG vaccination. Which of the following side effects is the neonate most likely to develop after vaccination?

Accepted Answer

Ulceration

Answer

Fever

Answer

Osteomyelitis

Answer

Regional lymphadenitis

Question 5

For how many days must residual weakness be observed in a case of acute flaccid paralysis to confirm poliomyelitis?

Accepted Answer

60 days

Answer

30 days

Answer

42 days

Answer

90 days

Question 6

What is the recommended Tetanus Toxoid (TT) vaccination schedule for a primigravida woman during pregnancy?

Accepted Answer

Two doses, one month apart, administered as soon as possible during pregnancy.

Answer

One dose in the second trimester.

Answer

Two doses, one month apart, in the second trimester.

Answer

One dose administered anytime as soon as possible during pregnancy.

Question 7

Which of the following is NOT a characteristic of the polio vaccine?

Accepted Answer

Achieving 100% immunization coverage is a characteristic.

Answer

Maintenance of cold chain is crucial.

Answer

The killed vaccine is effective in India.

Answer

Five doses of OPV are administered.

Question 8

Two girls in the same class are diagnosed with meningococcal meningitis. Their 12-year-old close friend is in fear of contracting the disease. What advice should be given to her?

Accepted Answer

Two doses of conjugate vaccine

Answer

Two doses of polysaccharide vaccine

Answer

Single dose of meningococcal vaccine

Answer

No vaccine needed as exposure has already occurred

Question 9

Which of the following is NOT true about measles?

Accepted Answer

Secondary attack rate is 30-40%

Answer

Incubation period is 10-14 days

Answer

Subcutaneous vaccine is available

Answer

Vaccine is live attenuated

Question 10

Which of the following statements is TRUE about acellular pertussis vaccine EXCEPT?

Accepted Answer

It is superior to whole-cell pertussis vaccine (wP).

Answer

It is a toxoid.

Answer

The acellular component confers the same immunity as the cellular one.

Answer

It can be administered as both primary and booster immunization.

Immunization and Vaccine-Preventable Diseases — MCQs

Immunization and Vaccine-Preventable Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?